Gastrointestinal Cancers: 2021 ASCO Annual Meeting Highlights for the Advanced Practitioner
Nina N. Grenon, DNP, AGCNP-BC, AOCN®
Dana-Farber Cancer Institute
J Adv Pract Oncol 2021;12(6):602-608 |
© 2021 Harborside™
Nina N. Grenon, DNP, AGCNP-BC, AOCN®, of Dana-Farber Cancer Institute, evaluates data on single and dual immunotherapy for advanced esophageal squamous cell carcinoma; maintenance therapy for metastatic colorectal cancer; a HER2-targeted therapy for colorectal cancer; adjuvant therapy for resected esophageal cancer and gastroesophageal junction cancer; and standard of care for patients with advanced biliary tract cancer.
For access to the full length article, please sign in